BOZEN, Italy, December 29 /PRNewswire/ -- Health Robotics today announced that it has signed a definitive agreement with the Devon International Group (DIG), whereby DIG has acquired the exclusive rights to Health Robotics' CytoCare(TM) and i.v.STATION(TM) robots in the People's Republic of China. Health Robotics solutions offer unique benefits with great appeal to Government and Hospital officials in China, such as eliminating human handling of chemotherapy and other hazardous drugs during preparation, greatly improving accuracy, and reducing potentially fatal medication errors. DIG will initially staff its Health Robotics product team at its Beijing and Shanghai office locations, in addition to planned local manufacturing operations.
CytoCare(TM) is the world's first and only automated robotic system for the safe preparation of hazardous patient-specific IV medications. Originally developed for Cancer Therapy, CytoCare(TM) has also been proven to compound Monoclonal Antibodies Therapy IV Admixtures to treat patients with Crohn's disease, Organ Transplants, Multiple Sclerosis, Rheumatoid Arthritis, and Infectious Diseases. i.v.STATION(TM) is the world's first and only automated, point-of-care-distributed, and fail-safe robotic system for the sterile and accurate preparation of non-hazardous IV Admixtures.
"Given DIG's strong presence in the People's Republic of China with some
of our other high-tech manufacturing subsidiaries, we embarked in due
diligence with our local partners, Government officials, and leading
healthcare providers to determine if this was the right time to bring Health
Robotics' unique technology to China. Increased safety for patients and
clinicians, higher accuracy of IV Admixtures, reduced waste, and improved
efficiency of hospitals' pharmacy workflow are among the key benefits that I
have witnessed in North America for both CytoCare(TM) and i.v.STATION(TM).
After I personally me
|SOURCE Health Robotics SRL|
Copyright©2008 PR Newswire.
All rights reserved